TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02415153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT00995839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous infusion of terlipressin
Description: Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin
Description: Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terlipressin bolus administration
Description: intravenous terlipressin bolus administration at the dose of 0.5 mg
Study: NCT02361112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib combined with capecitabine
Study: NCT01806168

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Magstim Super Rapid-2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Magstim Super Rapid-2

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS
Description: Magstim Super Rapid-2
Study: NCT04152681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
Study: NCT00433550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: given IV
Study: NCT04348708

Intervention type: GENETIC
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
Study: NCT05567367

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
Study: NCT04348708

Intervention type: GENETIC
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene

Intervention type: GENETIC
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
Study: NCT05567367

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil Oral Tablet
Description: 20 mg oral vardenafil tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil Oral Tablet
Description: 20 mg oral vardenafil tablet.
Study: NCT03131167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP639 (n=60)
Description: Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator (n=24)
Description: Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
Study: NCT04184557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staying Calm in the OR
Description: Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) ir Mindfulness Self Compassion (MSC).
Study: NCT02762084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study: NCT03980262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Children, Healthy Families+ (HCHF+)
Description: HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
Study: NCT02789644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
Study: NCT03980262

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Money Smart
Description: Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
Study: NCT01908868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Mediastinal and hilar lymph node aspiration using endobronchial ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TBNA
Description: Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial and transbronchial biopsy
Description: Endobronchial and transbronchial lung biopsy using flexible bronchoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endobronchial and transbronchial biopsy
Description: Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
Study: NCT01781962

Intervention type: OTHER
Intervention: No Treatment
Description: No Treatment was given in this study.
Study: NCT04552600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuvastatic
Description: Phase 1b Interventional, multi-centered, double-masked, randomized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Phase 1b Interventional, multi-centered, double-masked, randomized
Study: NCT00320528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
Study: NCT04071782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Coated Balloon
Description: SELUTION DCB will be used during lower limb angioplasty for treatment of lesions that are TASC C and D, in patients with Critical Limb Ischemia
Study: NCT00336934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Description: Given orally daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally daily.
Study: NCT03514719

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-avelumab PET
Description: 89Zr-avelumab injection followed by 89Zr-Avelumab PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging
Study: NCT00320528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
Study: NCT03276598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Treatment for four weeks. Dose: 5 mg o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Treatment for four weeks. Dose: 5 mg o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Treatment for four weeks. Dose: 25 mg o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Treatment for four weeks. Dose: 50 mg o.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for four weeks. Dose: 1 tablet per day.
Study: NCT01734447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
Study: NCT01468181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Study: NCT01734447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
Study: NCT01848574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized multifaceted information procedure to improve patients' comprehension
Study: NCT03747393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoD/VA CPG Core Set + PT
Description: Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DoD/VA CPG Core Set
Description: The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoD/VA CPG Core Set
Description: The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
Study: NCT01167569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5 % Dextrose Water or Normal Saline
Description: 100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
Study: NCT01429467

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)
Description: Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
Study: NCT02993835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe54
Description: Fe salt enriched with Fe 54 isotopes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe57
Description: Fe salt enriched with Fe 57 isotopes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labeled iron salt Fe58
Description: Fe salt enriched with Fe 58 isotopes
Study: NCT00372632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine
Description: The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The control group receives placebo similar in taste and appearance to to the experimental arm
Study: NCT02815085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RecoverLINK technology
Description: HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period
Study: NCT01730807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntellaTip MiFi XP Catheter
Description: Temperature controlled ablation catheter
Study: NCT01339871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose 400 mg orally daily of 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting dose 100 mg orally daily of 28 day cycle.
Study: NCT03398694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Stereotactic radiosurgery will be delivered on all patients utilizing gamma knife or linear accelerator based techniques as per RTOG-9005 dosing criteria (Section 11 Table 1) based on tumor diameter with the exception that the largest lesion diameter to be treated with 15 Gy will be 5 cm. All apparent, previously untreated brain metastases will be treated with radiosurgery at this time.~Radiosurgery will be performed 1-4 days prior to surgical resection. Vital signs and MRI Brain planning scan will be performed on the day of radiosurgery prior to the procedure.
Study: NCT02909790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curve Low Level Laser Therapy
Description: Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Curve Low Level Laser Therapy
Description: Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.).
Study: NCT05002595

Intervention type: DRUG
Intervention: H. pylori eradication
Description: Antimicrobial agents for H. pylori eradication

Intervention type: DRUG
Intervention: H. pylori eradication
Description: Antimicrobial agents for H. pylori eradication
Study: NCT03197948

Intervention type: OTHER
Intervention: Internet-Based Intervention
Description: Complete questionnaire via a smartphone application
Study: NCT04968093

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-based therapy.
Description: Educational. Patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. Patients will be encouraged to restrict use of acute medications to headaches and to engage in regular physical activity, avoiding skipping meals, remain well hydrated, maintain a regular sleep.~Mindfulness therapy. The intervention is delivered in small groups and consisted of 7 weekly group sessions. It was aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. Each session was conducted by a neurologist and a psychologist. To patients were asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations. Intervention's main topics: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts.
Study: NCT03988933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin double dose
Description: Double dose of rifampin for 2 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin triple dose
Description: Triple dose of rifampin for 2 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin standard dose
Description: Standard dose of rifampin for 4 months.
Study: NCT00130507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT00970489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega -3 fatty acids
Description: 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive Oil capsules
Study: NCT03933449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: IV infusion
Study: NCT03191552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPIO
Description: SPIO (stabilizing input pressure orthosis) 2 hours will receive conventional exercise therapy with the garment on during 2 hours. SPIO 6 hours group wore the SPIO 4 hours more in addition to 2 hours during therapy.~SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.~(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPIO
Description: SPIO (stabilizing input pressure orthosis) 2 hours will receive conventional exercise therapy with the garment on during 2 hours. SPIO 6 hours group wore the SPIO 4 hours more in addition to 2 hours during therapy.~SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.~(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Description: range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional exercises
Description: range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional exercises
Description: range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills